Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Aran Singanayagam, Stefano Aliberti, Catia Cillóniz, Antoni Torres, Francesco Blasi, James D. Chalmers. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia. Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016

Member's Comments

No comment yet.

Related content which might interest you: The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Safety and efficacy of CURB65 guided antibiotic therapy in community-acquired pneumonia Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011 Community-acquired pneumonia: severity and antibiotic treatments Source: ERS Course 2018 - Respiratory Infections Year: 2018 Novel Pseudomonas aeruginosa scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumònia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 Update on therapeutic strategies in community-acquired pneumonia    Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice Year: 2017 Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Predictor factors of empirical antimicrobial treatment failure in community-acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 357s Year: 2002 Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia Year: 2018 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Use of diagnostic tests and antibiotics in community-acquired pneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 639s Year: 2005 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Trends in empiric antimicrobial therapy and efficiency of care for community-acquired pneumonia in hospitalized Belarussian patients Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 International Guideline concordance of empiric antibiotic use in community-acquired pneumonia Source: Virtual Congress 2020 – Antibiotic therapy for pneumonia and pleural infections Year: 2020 Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning Source: Eur Respir J, 54 (6) 1900824; 10.1183/13993003.00824-2019 Year: 2019